The World Health Organisation has prequalified the first hepatitis C virus self-test which can provide a critical support in expanding access to testing and diagnosis, accelerating global efforts to eliminate hepatitis C.
Hepatitis C is a viral disease that primarily causes inflammation of the liver, but the effects can be felt throughout the body.
According to the Centres for Disease Control and Prevention, Hepatitis C is known as the silent killer because initial infection usually has few to no symptoms. But over time, the virus can slowly cause damage to the liver. It can cause liver cancer, liver failure and death.
The self-test product, called OraQuick HCV self-test, manufactured by OraSure Technologies, is an extension of the pre-qualified, OraQuick® HCV Rapid Antibody Test which was initially prequalified by WHO in 2017 for professional use.
WHO disclosed this in a press statement on Wednesday.
The UN agency said the self-test version, specifically designed for use by lay users, provides individuals with a single kit containing the components that are needed to perform the self-test.
WHO recommended HCV self-testing in 2021 to complement existing HCV testing services in countries. The recommendation was based on evidence demonstrating its ability to increase access to and uptake of services, particularly among people who may not otherwise test.
It said the national-level HCVST implementation projects, largely supported by Unitaid, have shown high levels of acceptability and feasibility, as well as empowering people through personal choice, autonomy and access to stigma-free self-care services.
“Every day 3,500 lives are lost to viral hepatitis. Of the 50 million people living with hepatitis C, only 36 per cent had been diagnosed, and 20 per cent have received curative treatment by the end of 2022,” says the WHO Director for the Department of Global HIV, Hepatitis and STI Programmes, Dr. Meg Doherty.
Doherty added that “The addition of this product to the WHO prequalification list provides a safe and effective way to expand HCV testing and treatment services, ensuring more people receive the diagnoses and treatment they need, and ultimately contributing to the global goal of HCV elimination.”
WHO’s prequalification programme for in vitro diagnostics evaluates a range of tests, including those used for the detection of antibodies to HCV. The programme assesses IVDs against quality, safety and performance standards. It is a cornerstone in supporting countries in achieving high-quality diagnosis and treatment monitoring.
“The availability of a WHO prequalified HCV self-test enables low- and middle-income countries have access to safe and affordable self-testing options which is essential to achieving the goal of 90% of all people with HCV to be diagnosed,” says the WHO Director for the Department of Regulation and Prequalification, Dr Rogério Gaspar.
“This achievement contributes to improving access to quality-assured health products for more people living in low-income countries,” Gasper added.
The global health body pledged to WHO continue to assess additional HCV self-tests, support evidence-based implementation, and work with communities to expand available options to all countries.
